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ABSTRACT 
Purpose: This review sought to synthesize existing evidence to establish if patients 
who present to the Emergency Department (ED) and are administered antibiotics 
immediately (within 1 hour) or later (>1 hour) and then subsequently diagnosed with 
a sepsis illness have different outcomes (mortality).   
Methods: Data sources. A search of Pubmed, Embase, Cochrane CENTRAL and 
CINAHL, using MeSH descriptors ‘sepsis’, ‘systemic inflammatory response 
syndrome’, ‘mortality’, ‘emergency’ and ‘antibiotics’, was performed to identify 
studies reporting time to antibiotic administration and mortality outcome in patients with sepsis.  
Study selection. Included studies (published in English between 1990-2016) listed 
patient mortality based on time to antibiotic administration.  
Data extraction. Studies were evaluated for methodological quality and data were 
extracted using a data extraction form tailored to this study.  
Data synthesis. From an initial pool of 582 potentially relevant studies, eleven studies 
met our inclusion criteria of which ten had quantitative data for meta-analysis.  
Analytical methods. Three different models; a random effects (RE), a bias adjusted 
quality-effects (synthetic bias; QE), and its bias unadjusted variant inverse variance 
heterogeneity (IVhet) model, were used to undertake the meta-analysis. 
Findings: Pooled results suggest a significant 33% reduction in mortality odds for 
immediate (within 1 hour) compared to later (>1 hour) antibiotic administration (OR 
0.67; 95% CI 0.59 – 0.75). 
 
Implications: Immediate antibiotic administration (<1 hour) appeared to reduce 
patient mortality. There was some minor negative asymmetry suggesting that the 
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evidence may be biased towards the direction of effect. Nevertheless, this study 
provides strong evidence for early, comprehensive, sepsis management in the ED. 
 
INTRODUCTION 
It is estimated that there are 18 million cases of sepsis per year worldwide. More than 
17,000 of those episodes are in Australia and that number is projected to grow at a 
rate of 1.5% per year 1. Sepsis has high mortality rate and results in significant 
morbidity 2. 
Sepsis arises when the body’s immune response to infection causes a widespread 
inflammatory response. Often described under the umbrella term “sepsis”, there is an 
acknowledged continuum now assessed using a sequential [sepsis-related] organ 
failure assessment3 and sometimes assessed using a staging score4. Each form of 
sepsis is progressively more severe, with a higher mortality rate. Septic shock (with 
acute organ dysfunction) has a mortality rate up to 46% 5. Sepsis is a time sensitive 
illness where rapid, relatively uncomplicated treatment (including the administration 
of antibiotics) can translate into lives saved 6. 
International consensus guidelines recommend initiating broad-spectrum 
antibiotic coverage immediately (within the first hour) once a diagnosis of severe 
sepsis and septic shock is considered 7. This recommendation is largely based on one 
large retrospective study by Kumar et al and expert consensus 8. Kumar et al. 8 
estimated that mortality rate increases by 7.6% with every hour delay in starting 
antimicrobial therapy in the first 6 hours after hypotension onset. Further, it was 
demonstrated that effective antimicrobial administration within the first hour of 
documented hypotension was associated with increased survival to hospital discharge 
in septic shock 8. 
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A Cochrane review of ‘early versus late pre-intensive care unit admission broad 
spectrum antibiotics for severe sepsis in adults’ did not locate any randomized 
controlled trials 9. They were, therefore, unable to make any specific 
recommendations other than that there is a need for large prospective double blind 
RCTs examining the efficacy of immediate (within 1 hour) versus later broad 
spectrum antibiotics in adult severe sepsis patients 9. In the interim, research derived 
from other (less rigorous) study types incorporating broader (additional) sepsis 
diagnoses may be useful to guide practice in the emergency setting 10. 
The aim of this systematic review and meta-analysis was to review and assess the 
current evidence regarding patients who present to the ED and are diagnosed with a 
Sepsis illness (i.e. Systemic inflammatory syndrome (SIRS), sepsis, severe sepsis, 
sepsis with septic shock and sepsis with organ dysfunction) in terms of in-hospital 
mortality outcomes for those who are administered antibiotics immediately (within 1 
hour) or later (>1 hour). 
 
METHODS 
Identification of studies 
This review was conducted based on the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines11. Ethical review is not 
required for a review study. We searched EMBASE, MEDLINE, CINAHL and 
Cochrane Central Register of Controlled Trials (CENTRAL). All terms were mapped 
to the appropriate MeSH/EMTREE/CINAHL headings and “exploded”. Search terms 
used included: ‘sepsis’, ‘systemic inflammatory response syndrome’, ‘mortality’, 
‘emergency’ and ‘antibiotic agent’. Additional search strategies (i.e. Pubmed, google, 
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reference lists of articles, forward and backwards reference chaining) were used to 
identify further articles for potential inclusion12, 13. 
 
Study selection 
Studies were included if they were published in English language during 1990-
2016, as the ‘surviving sepsis’ campaign was formulated in 1990 and guidelines of 
early, goal-directed therapy (which included early antibiotics) were produced at that 
time. All original research studies that included the term ‘sepsis’, included associated 
with EDs as a setting for antibiotic administration, and described outcomes that 
include mortality pertaining to early (<1 hour) versus late (>1 hour) administration of 
broad spectrum antibiotics were included11, 13. Studies were excluded if they were 
qualitative in nature, did not include an assessment of early versus late antibiotic 
administration and did not include some measure of mortality as an outcome 14.  
 
Data extraction and quality assessment  
Two authors (JCl & AJ) independently undertook the initial screen for article 
inclusion using the Rayyan platform to facilitate study selection15. Clarification of 
inclusion was resolved by discussion with other authors. The article selection process 
is displayed in Figure 1. Data extracted from each study included author, year and 
country of publication, sample size, study design, main outcomes measured and 
results (see Tables 1 and 2).  
The quality of articles that met inclusion criteria were independently reviewed 
and assessed by two authors (AJ, VS) with clarification resolved using a third author 
(JC). Included studies were assessed by careful reading of the manuscripts for their 
methodological quality using National Health and Medical Research Council 
5  
(NHMRC) guidelines16 and a generic scale created by the authors (presented in Table 
3). The latter includes 17 questions (with subsections to total 25 in all) divided into 5 
components that explore potential design bias, selection bias, information bias, 
potential for confounding and analytical bias17.  One point was given for each study 
criterion cited in the study that limited bias; up to a maximum of 25 points, and this 
was summed into a univariate quality score out of 25. The proforma for the generic 
quality assessment scale is included in the supplemental material. This score was used 
to rank studies for use with the quality effects model 18. 
 
Statistical analysis and data synthesis 
The in-hospital mortality odds ratios for early versus late antibiotic administered 
groups were pooled using three different meta-analytic models 17-20. Hazard ratios 
reported in some studies were interpreted as odds ratios in this analysis. Of the three 
models, two were the quality-effects model (QE) and the inverse variance 
heterogeneity model (IVhet) which both use a quasi-likelihood based variance 
structure without distributional assumptions. The latter thus have coverage 
probabilities for the CI at the 95% nominal level and have been documented to have a 
better performance when compared to the conventional third model we used: the 
random effects (RE) model 17, 18. Cochran's Q test and 2I were used to assess 
heterogeneity amongst studies. 2I >50% was considered to indicate practically 
significant heterogeneity. Publication bias was assessed via funnel plot asymmetry. 
All meta-analyses were conducted using MetaXL version 5.2 21.   
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RESULTS 
Application of the study inclusion/exclusion process (Figure 1) resulted in 11 
articles. Data for the 11 studies were developed between 2005 and 2013 with 
subsequent publication dates ranging from 2009 to 2016 (see Table 1). The trials were 
conducted in various countries: five in USA (including one multi-continent study 
including Europe)6, 22-25, one included a broad grouping ‘Europe’26, and one each in 
Korea27, Canada28, The Netherlands29, Australia30 and Iran31 (see Table 1). The 
population of each study varied and included SIRS, sepsis, severe sepsis and septic 
shock. The number of patients included in the study varied between 85 and 17,990. In 
terms of study type, one was a randomized control trial 22, six were retrospective 
cohort studies 6, 24, 27-30, three were prospective cohort studies 23, 26, 31 and one was a 
pre-post observational study25. Eight of the studies were set exclusively in the 
emergency department 6, 22, 24, 25, 27, 29-31; and while all involved patients had an ED 
episode of care, two were the result of data collected eventually from the ICU 23, 26 
and one from data collected from general medical, general surgical and ICU areas 28 
following ED administration of antibiotics. 
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Figure 1.  PRISMA 2009 Flow Diagram Article database source and schematic 
representation of the search processes with application of inclusion/exclusion criteria. 
The numbers of articles included in each step are shown numerically in each 
component of the process. 
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Table 1. Characteristics of studies included in the review  
Authors, Year, 
Reference 
When 
Trial 
Conducted 
Country Population 
Type 
Sepsis classification and definition used No. of 
Patients 
Study Type Trial setting 
where sepsis 
outcome 
was 
identified 
 
 
 
Ferrer et al., 
2009[26] 
2005 - 
2007 Europe 
SS 
SK 
SS:  sepsis associated with organ dysfunction 
unexplained by other causes 
S: respiratory dysfunction (bilateral pulmonary 
infiltrates with PaO2/FIO2 
<300), renal dysfunction (urine output <0.5 
ml/kg/hr for at least 2 hours or creatinine >2.0 
mg/dl), coagulation abnormalities (International 
Normalized Ratio [INR] >1.5 or a partial 
thromboplastin time [PTT] >60 seconds), 
thrombocytopenia (platelet count <100,000/uL), 
hyperbilirubinemia (total plasma bilirubin >2.0 
mg/dl), hypoperfusion (lactate >18 mg/dl), or 
hypotension (systolic blood pressure <90 mm Hg, 
mean arterial pressure <65 mm Hg, or a reduction 
in systolic blood pressure >40 mm Hg from 
baseline measurements). 
SK acute circulatory failure (systolic blood 
pressure <90 mm Hg, mean arterial pressure <65 
mm Hg, or a reduction in systolic blood pressure 
>40 mm Hg from baseline) despite adequate 
volume resuscitation. 
2796 Prospective Cohort ICU 
Gaieski et al., 
2010[6] 
2005 - 
2006 USA 
SS 
SK As per Surviving Sepsis Guidelines [7] 261 
Retrospective 
Cohort ED 
 
Puskarich et 
al., 2011[22] 
2007 - 
2009 USA SK 
SK: the patient developed two or more SIRS 
criteria and either a systolic blood pressure 90 
mmHg after a minimum of 20-mL/kg rapid volume 
291 RCT† ED 
9  
challenge or a blood lactate concentration of at 
least 4 mmol/L. 
O’Neill et al., 
2012[24] 
2008-
2009 USA 
SS 
SK As per Surviving Sepsis Guidelines [7] 85 
Retrospective 
Cohort ED 
Jalili et al., 
2013[31] 
2007 - 
2009 Iran S 
S: presence of at least two criteria of SIRS and 
procalcitonin levels ≥2 μg/l 145 
Prospective 
Cohort ED 
 
Ferrer et al., 
2014[23] 
2005 - 
2010 
USA 
South 
America 
Europe 
SS 
 
SS: having a suspected site of infection, two or 
more SIRS criteria, and one or more organ 
dysfunction criteria [3, 34]  
17990 Prospective  Cohort ICU 
 
Ryoo et al 
2015[27] 
 
2010-
2012 
Korea SK 
SK: refractory hypotension, specifically, systolic 
blood pressure <90 mm Hg or mean arterial 
pressure <70 mm Hg requiring vasopressors despite 
adequate fluid therapy, or a blood lactate 
concentration of at least 4 mmol/L 
426 Retrospective Cohort ED 
De Groot et 
al., 2015[29] 
2011-
2013 
The 
Netherlands S 
As per Surviving Sepsis Guidelines[7] segregated 
by PIRO scores[4] 1168 
Prospective 
observational 
cohort 
ED 
Wisdom et 
al., 2015[30] 2012 Australia 
S 
SS 
As per International Sepsis definitions 
conference[36] 220 
Retrospective 
Cohort ED 
Narayanan et 
al., 2016[25] 
2012-
2013 USA 
SS 
SK As per Surviving Sepsis Campaign[7] 214 
Pre-Post 
observational  ED 
 
Mok, 
Christian et 
al., 2014[28] 
 
2009-
2010 
 
Canada 
SS 
SK 
SS: sepsis associated with organ dysfunction, 
hypoperfusion, or hypotension. 
SK: sepsis with hypotension despite adequate fluid 
resuscitation 
100 Retrospective Cohort 
Hospital-
wide 
ED, Emergency Department; ICU, Intensive Care Unit; PIRO, predisposition, infection (or insult), response and organ dysfunction (PIRO) staging of sepsis; 
S, Sepsis; SIRS, systemic inflammatory response syndrome; SS, severe sepsis; SK, septic shock; SSC, surviving sepsis campaign[48]; †Detailed methodology for this 
study[27] was outlined elsewhere[38]. 
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Table 2. Summary of Study Results 
 
Authors, 
Reference 
Type of 
Antibiotic used 
AU, 
appropriatenes
s of antibiotic 
measured AA 
(Yes/No) 
Number of 
patients 
AB ≤1 hour 
group 
Number of 
patients in 
AB >1 hour 
group 
In hospital 
Mortality 
(AB ≤1 hour) 
N (%) 
In hospital 
Mortality 
(AB >1 hour) 
N (%) 
OR 95% CI p 
Ferrer et al., 
2009[26] 
AU (N), 
AA (N) 
510 
(18.2) 
1851 
(81.5) 
 
175 
(34.3%) 
792 
(42.8%) 
0.67 0.5-0.9 0.001¥ 
Gaieski et al., 
2010[6] 
AU (N), 
AA (Y) 
41 
(15.7%) 
220 
(84.3%) 
8 
(19.5%) 
73 
(33.2%) 
     0.3 0.11-0.83 0.02‡ 
Puskarich et 
al., 2011[22] 
AU (N), 
AA (Y) 
65 
(22.3%) 
226 
(77.7%) 
11 
(16.9%) 
44 
(19.5%) 
^0.55 0.23-1.35 0.69‡ 
O’Neill et al., 
2012[24] 
AU (N), 
AA (N) 
65 
(77.4%) 
19 
(22.6) 
15 
(23.1%) 
4 
(21.1) 
0.89 0.31-2.55 NS¥ 
Jalili et al., 
2013[31] 
AU (N), 
AA (Y) 
26 
(17.9%) 
118 
(81.3%) 
1 
(3.8%) 
30 
(25.4%) 
0.12 0.02-0.90 0.05‡ 
Ferrer et al., 
2014[23] 
AU (Y), 
AA (N) 
4728 
(26.3%) 
13265 
(73.7%) 
1508 
(31.9%) 
4112 
(31%) 
^0.66 0.59-0.74 0.001§ 
Ryoo et al 
2015[27] 
AU (N), 
AA (Y) 
150 
(35.2%) 
276 
(64.8) 
29 
(19.3%) 
121 
(19.3%) 
0.81 0.45-1.45 NS€ 
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de Groot et 
al., 2015[29] 
AU(Y) 
AA(Y) 
-- -- -- -- ^**0.68 
^**0.98 
^**0.71 
0.5-0.95a 
0.72-1.33b 
0.43-1.19c 
 
Wisdom et 
al., 2015[30] 
AU(Y) 
AA(Y) 
-- -- -- -- ^**0.57 0.2-1.33 0.08 
Narayanan et 
al., 2016[25] 
AU(Y) 
AA(Y) 
133 
(62%) 
81 
(38%) 
-- -- 0.64 0.26-1.57 <0.001 
Mok, 
Christian et 
al., 2014[28] 
AU (Y) 
AA (Y) 
6 
(6.0%) 
94 
(94.0%) 
 
N/A 
 
N/A 
- - ∫- 
 
Captions and abbreviations used: AU, antibiotics used; AA, appropriateness of antibiotics; OR, Odds ratio of in-hospital 
mortality for cases where AB is given >1 hour; CI, Confidence Interval; p, probability-values  
‡ Times given are for triage (“door”) to antibiotic administration  
§ For patients enrolled from the ED, time is defined as the time of triage to antibiotic administration. For patients admitted to the 
ICU from medical and surgical wards and for patients in ICU at time of diagnosis, time is determined by chart review for the 
diagnosis of septic shock to antibiotic administration. 
¥ Time is defined as time from noted diagnosis to antibiotic administration 
€ Time is defined as time from initial assessment to antibiotic administration 
∫ Time is defined as time from onset of sepsis/septic shock to antibiotic administration 
^data reversed for analysis **Hazard ratios reported a,b,c refer to three groupings of PIRO[4] (predisposition, infection (or insult), response and organ dysfunction) staging scores; a = 1-7, b = 8-14, c = >14 PIRO[4] 
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Results of the study quality assessment tools applied indicated that the included 
studies varied somewhat, but generally rated as mid- to high quality. There was only 
one randomized controlled trial (level II NHMRC). The remainder ranged in strength 
from III-2 to IV12. The Quality Scale provided some degree of study quality 
discrimination with scores ranging from 13 to 21.518 (see Table 3).. 
 
Table 3. Results of the quality assessment measures applied to the studies that 
were used to inform the review  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Captions and abbreviations used: NHMRC; National Health and Medical Research 
Council (Australia); *a = 1-7, b = 8-14, c = >14 using the PIRO 
 
  
 
Authors, 
Reference 
  Loss to  
follow up 
Adjustment for 
Confounders 
NHMRC level 
of evidence 
Quality  
  score 
Ferrer et al., 
2009[26] <15% Yes III-3 19/25 
Gaieski et al., 
2010[6] - Yes III-2 17/25 
Puskarich et 
al., 2011[22] <5% Yes II 21.5/25 
O’Neill et al., 
2012[24] <15% Yes III-S 14/25 
Jalili et al., 
2013[31] <15% Yes III-2 16/25 
Ferrer et al., 
2014[23] ~32% Yes III-3 20/25 
Ryoo et al 
2015[27] - Yes III-3 13/25 
De Groot et 
al., 2015[29] - Yes III-2 18/25a,b,c* 
Wisdom et 
al., 2015[30] - Yes III-3 17/25 
Narayanan et 
al., 2016[25]  Y III-3 16/25 
Mok, 
Christian et 
al., 2014[28] 
- N/A IV 13/25 
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Our primary outcome of interest was in-hospital mortality for immediate versus 
later administration of antibiotics. One study 28 only reported overall mortality rate, 
not differentiating between those administered antibiotics within or greater than 1 
hour and was excluded from the quantitative synthesis. The remaining ten studies 
compared in-hospital mortality between patients who had immediate (<1 hour) 
antibiotics, or not, given in the ED. These ten studies reported in-hospital mortality of 
between 4-34% for patients administered antibiotics immediately and between 19-43% 
mortality for patients administered antibiotics later (see Table 2). All studies 
contributing data for meta-analysis 6, 22-27, 29-31, reported an odds ratio of less than one, 
indicating that administration of antibiotics within 1 hour may make a difference in 
terms of mortality. Statistically significant impacts of time to antibiotic administration 
were reported in five of the ten studies 6, 23, 25, 26, 31. One study reported a range of odds 
ratios based on a predefined illness severity score 4, 29. 
While all 10 studies had a time to antibiotic of one hour or less as the exposure 
(see Table 2), the control for analysis varied from >1h to >6h 6, 22, 23, 27, 28, 31. Five 
studies reported on the type 23, 25, 28-30, and eight on the ‘appropriateness’ 6, 22, 25, 27-31, 
of the antibiotic administered with another stating that ‘antibiotic appropriateness’ had 
been established 31. In general, the studies considered antimicrobial therapy to be 
appropriate if the bacteria identified in blood culture was susceptible to at least one of 
the antibiotics administered empirically in the ED, based on the culture results taken 
at this point. 
 
Quantitative synthesis 
While three different models were used to undertake the meta analysis, only QE 
results are presented because the other results essentially concurred. The QE model 
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indicated an estimated 33% reduction in mortality odds with immediate antibiotic 
administration (OR 0.67; 95% CI: 0.59 – 0.75).  Cumulative forest plots with a 
sensitivity analysis excluding two influential studies (see Figure 2), demonstrate that 
significance of the results is not driven by the two largest studies (Ferrer et al. 23, 26) 
and without them the pooled odds for immediate vs. delayed antibiotic use was 0.70 
(95% CI 0.57, 0.87).  There was no heterogeneity of effects seen across studies 
(I2=9%; Q=12.13; p=0.35). 
 
Funnel and Doi plots 32 in Figure 3 indicated that there was minor negative 
asymmetry and therefore there may be some degree of publication related or small 
study bias favouring studies supporting early antibiotic administration. However 
asymmetry was minor and thus the effect reported is not likely to be grossly 
exaggerated.  
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Figure 2. Cumulative Forest plots using the QE method including all studies (top left), excluding the Ferrer et al 2014[23] study only (top right) 
and excluding both Ferrer et al 2014 and 2009[23, 26] studies (bottom left). CI, confidence interval; ES, effect size (all odds ratios except ** 
indicate hazard ratios). 
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Figure 3. Publication bias assessed via the Doi plot (left panel) and Funnel plot (right panel). Minor negative asymmetry, suggesting some 
publication bias is evident. ln, natural log; ES, effect size. 
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DISCUSSION  
The meta-analysis of the studies included in this review suggest that immediate 
antibiotic commencement can decrease the mortality odds from sepsis by up to an 
estimated 33% (OR 0.67; 95% CI 0.59 – 0.75).  The largest study showed a strong 
effect 23 with a confidence interval that ranged between 26 and 41% decrease in odds 
of mortality 23. All included studies, provided more or less similar effect sizes in this 
study because the quality rank of the studies were not very variable and study effects 
were homogenous (I2=9%)12, 32. The Doi plot (figure 3) shows only minor asymmetry 
and therefore the pooled odds ratio of 0.67 is probably a robust estimate. Thus, the 
overall data suggests a real clinical impact of early (ED) administration of antibiotics 
on patient mortality, supporting the earlier assertions of Kumar 8.  
 
This finding provides strong support for evidence-based guidelines that advocate 
earlier management with antibiotics of patients with sepsis. Although the ‘Surviving 
Sepsis Campaign’ international consensus guidelines recommend administering a 
broad-spectrum antibiotic within the first hour of recognizing severe sepsis and septic 
shock 7, this was largely based on expert opinions and a retrospective study 8, 34 and 
does not consider the time variations between arrival at hospital and recognition of 
sepsis. However this meta-analysis indicates that irrespective of the start point, earlier 
antibiotics are typically better for patients. It is possible that delay for clinical 
screening tools and confirmatory biochemical markers (such as lactate levels35) may 
compromise outcomes. 
The results of this meta-analysis do not provide a resolution to the optimal time 
frame beyond which delaying antibiotics can be deleterious for patients with sepsis 
but strongly suggest that antibiotics be administered as early as is feasibly possible. 
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Such timing is challenging because recording the initial time point (detection) is 
inconsistently defined within the literature. Starting time points used to determine 
time to antibiotic administration included time from; arrival, diagnosis, detection, 
recognition, and admission. This was possibly due to the settings in which the sepsis 
studies were undertaken. For example, in broad-based studies, patients recruited from 
ED often had the triage time logged as time of presentation whereas patients in the 
same studies that were recruited from general wards or ICU a chart review or 
equivalent was used to determine time of diagnosis and presentation 28, 30. Thus, 
studies undertaken in the ED were primarily focused on the early detection of sepsis, 
whereas studies undertaken in the ICU setting were focused more on the effectiveness 
of early goal directed therapy and could draw on additional information not typically 
available in the ED setting (such as APACHE II score) to guide care delivery.  
 
Five of the ten studies included in this review indicated a significantly reduced 
mortality when antibiotics were given within one hour (of arrival, from diagnosis, 
from detection, from recognition, from admission) compared to delayed 
administration of antibiotics (>1hr). The other six studies (including the study that did 
not contribute data to the meta analysis 28) showed no significant benefit of antibiotic 
administration within an hour but the pooled effects suggest that the latter could have 
been under-powered to detect such a benefit. Studies showing non-significant effects 
also varied in quality from the highest included to lower rated studies, so non-
significance was not just an effect of a poor study.  
 
There are two other issues that evidence suggests may be considered as important 
as that of timing and thus must be considered. First is the notion of ‘appropriate 
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antibiotic therapy’. Appropriateness usually means that the organism identified from 
culture was sensitive to the initial antibiotics administered. 36, 37.  One study that did 
not show any reduction in mortality in early antibiotic administration arm (≤1hour) 
did not measure the “appropriateness” of the antibiotics that were given in the ED 24, 
however other studies were contradictory such that the appropriateness of the 
antibiotic administered was associated with either no significant 28 or significant 6 
benefits of timing of administration <1 hour. Further research in this area is required 
to enhance not only the early recognition but also the appropriateness of treatment, 
including antibiotics, provided. Indeed, antibiotic appropriateness is becoming an 
increasing focus of sepsis studies, guided by local antibiotic stewards.  
 
The second critical issue to note regarding sepsis is the overall care bundle 
provided. Care bundles 38, 39 are generally guided by a specific protocol and examples 
include the Surviving Sepsis Campaign guidelines 7, ProCESS 39, 40 and, most recently, 
ARISE 41. Based on early goal-directed therapy, the outcomes from studies using 
these guidelines are not necessarily conclusive in whether early goal-directed therapy 
improves outcomes and is cost effective 42, however these overall analyses suggest 
that early goal-directed therapy can improve patients’ outcomes. 
 
Strengths and limitations  
A strength of our study is that we used several analytic approaches and they all 
concurred because heterogeneity was not seen across studies. Nevertheless we should 
point out that the conventional approach using the random effects (RE) model 19 is 
known to underestimate the statistical error which can lead to an overconfidence in 
the result when heterogeneity is present 43. The two other statistical approaches used 
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have been documented to have a better performance when compared to the RE 
method 18. 
 
There are several limitations to our study. The dominance by a single primary 
author (the two Ferrer et al papers23, 26) accounting for 74% of the weight from the 10 
studies included is a relative limitation. However, exclusion of these studies in a 
sensitivity analysis did not make a difference to the pooled estimate (see Figure 2). 
Our search strategy was carefully planned, and article exclusion criteria were strictly 
adhered to, perhaps limiting the scope of included evidence 44. Our main outcome of 
interest was in-hospital mortality. Other outcomes that reflect care quality may also be 
useful to consider when undertaking reviews such as this one. Another limitation was 
the varied definitions of timing, as discussed above. There were also varying 
definitions, ‘grades’ of sepsis used for study inclusion and varying sepsis detection 
processes within these studies. While some studies included patients with severe 
sepsis and septic shock 6, 26, others included only patients with septic shock 22. 
However, the pattern of results from these studies did not vary widely. In studies that 
compared wards where sepsis was detected, a higher mortality rate was noted in the 
‘ward groups’ versus the ‘ED groups’[28]. Additionally, the study settings had 
varying sepsis detection processes, with multi-site studies consistently demonstrating 
that in hospital mortality from detection of sepsis in the ward compared to ED 
increased 23, 28, 37.  
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CONCLUSIONS 
The evidence base assessed here indicates that administering appropriate 
antibiotics immediately sepsis is recognized appears to reduce mortality in patients 
with sepsis and severe sepsis. Recognizing the signs of sepsis early can be sometimes 
difficult. On the basis of this evidence implementation of international standardized 
guidelines for ED clinician’s regarding i) early detection and ii) appropriate early 
treatment of sepsis is required. 
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Supplementary material 
 
Pubmed 
("Anti-Bacterial Agents"[Mesh] OR Antibacterial[tiab] OR Antibacterials[tiab] OR 
Antibiotics[tiab] OR Antibiotic[tiab] OR Antimicrobial[tiab] OR 
Antimicrobials[tiab]) 
AND 
("Sepsis"[Mesh] OR Sepsis[tiab] OR “Septic shock”[tiab] OR “Systemic 
inflammatory response syndrome”[tiab] OR Septicemia[tiab] OR Septicemias[tiab]) 
AND  
("Mortality"[Mesh] OR “Survival Rate"[Mesh] OR "Survival Analysis"[Mesh] OR 
Mortality[tiab] OR Death[tiab] OR Deaths[tiab] OR Survival[tiab]) 
AND 
("Emergency Service, Hospital"[Mesh] OR “Emergency service”[tiab] OR 
“Emergency services”[tiab] OR “Emergency department”[tiab] OR “Emergency 
departments”[tiab] OR “Emergency Units”[tiab] OR “Emergency Unit”[tiab] OR 
ED[tiab] OR "Intensive Care Units"[Mesh] OR "Intensive Care Units"[tiab] OR 
"Intensive Care Unit"[tiab] OR ICU[tiab] OR ICUs[tiab]) 
AND 
("Time-to-Treatment"[Mesh] OR Timing[tiab] OR “Time to”[tiab] OR Hour[tiab] OR 
Hours[tiab]) 
AND 
(Administration[tiab] OR Appropriate[tiab] OR Appropriateness[tiab] OR 
Compliance[tiab]) 
AND 
(“randomized controlled trial”[pt] OR “controlled clinical trial”[pt] OR 
randomized[tiab] OR randomised[tiab] OR placebo[tiab] OR randomly[tiab] OR 
trial[tiab] OR groups[tiab] OR "Epidemiologic Studies"[Mesh] OR “case-control 
studies”[Mesh] OR “Cohort Studies”[Mesh] OR “case control”[tiab] OR Cohort[tiab] 
OR “Follow up”[tiab] OR Observational[tiab] OR longitudinal[tiab] OR 
Prospective[tiab] OR retrospective[tiab] OR “cross sectional”[tiab] OR “Cross-
Sectional Studies”[Mesh] OR Investigated[tiab] OR Analysis[tiab]) 
NOT 
(Animals[Mesh] not (Animals[Mesh] and Humans[Mesh]) 
  
Cochrane CENTRAL 
([mh "Anti-Bacterial Agents"] OR Antibacterial:ti,ab OR Antibacterials:ti,ab OR 
Antibiotics:ti,ab OR Antibiotic:ti,ab OR Antimicrobial:ti,ab OR Antimicrobials:ti,ab) 
AND 
([mh Sepsis] OR Sepsis:ti,ab OR "Septic shock":ti,ab OR "Systemic inflammatory 
response syndrome":ti,ab OR Septicemia:ti,ab OR Septicemias:ti,ab) 
AND 
([mh Mortality] OR [mh "Survival Rate"] OR [mh "Survival Analysis"] OR 
Mortality:ti,ab OR Death:ti,ab OR Deaths:ti,ab OR Survival:ti,ab) 
AND 
([mh "Emergency Service, Hospital"] OR "Emergency service":ti,ab OR "Emergency 
services":ti,ab OR "Emergency department":ti,ab OR "Emergency departments":ti,ab 
OR "Emergency Units":ti,ab OR "Emergency Unit":ti,ab OR ED:ti,ab OR [mh 
"Intensive Care Units"] OR "Intensive Care Units":ti,ab OR "Intensive Care 
Unit":ti,ab OR ICU:ti,ab OR ICUs:ti,ab) 
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AND 
([mh Time-to-Treatment] OR Timing:ti,ab OR “Time to”:ti,ab OR Hour:ti,ab OR 
Hours:ti,ab) 
AND 
(Administration:ti,ab OR Appropriate:ti,ab OR Appropriateness:ti,ab OR 
Compliance:ti,ab) 
 
 
  
Embase 
('antiinfective agent'/exp OR Antibacterial:ti,ab OR Antibacterials:ti,ab OR 
Antibiotics:ti,ab OR Antibiotic:ti,ab OR Antimicrobial:ti,ab OR Antimicrobials:ti,ab) 
AND 
('Sepsis'/exp OR Sepsis:ti,ab OR "Septic shock":ti,ab OR "Systemic inflammatory 
response syndrome":ti,ab OR Septicemia:ti,ab OR Septicemias:ti,ab) 
AND 
('mortality'/exp OR 'Survival Rate'/exp OR 'survival'/exp OR Mortality:ti,ab OR 
Death:ti,ab OR Deaths:ti,ab OR Survival:ti,ab) 
AND 
('emergency health service'/exp OR “Emergency service”:ti,ab OR "Emergency 
services":ti,ab OR "Emergency department":ti,ab OR "Emergency departments":ti,ab 
OR "Emergency Units":ti,ab OR "Emergency Unit":ti,ab OR ED:ti,ab OR  'intensive 
care unit'/exp OR "Intensive Care Units":ti,ab OR "Intensive Care Unit":ti,ab OR 
ICU:ti,ab OR ICUs:ti,ab) 
AND 
('time to treatment'/exp OR Timing:ti,ab OR “Time to”:ti,ab OR Hour:ti,ab OR 
Hours:ti,ab) 
AND 
(Administration:ti,ab OR Appropriate:ti,ab OR Appropriateness:ti,ab OR 
Compliance:ti,ab) 
AND 
(randomized:ti,ab OR randomised:ti,ab OR placebo:ti,ab OR randomly:ti,ab OR 
trial:ti,ab OR groups:ti,ab OR 'epidemiology'/exp OR “case control”:ti,ab OR 
Cohort:ti,ab OR "Follow up":ti,ab OR Observational:ti,ab OR longitudinal:ti,ab OR 
Prospective:ti,ab OR retrospective:ti,ab OR "cross sectional":ti,ab OR 
Investigated:ti,ab OR Analysis:ti,ab) 
 
CINAHL 
((MH "Antiinfective Agents+") OR Antibacterial OR Antibacterials OR  Antibiotics 
OR  Antibiotic OR  Antimicrobial OR  Antimicrobials) 
AND 
((MH  "Sepsis+") OR Sepsis OR "Septic shock" OR  "Systemic inflammatory 
response syndrome" OR Septicemia OR  Septicemias) 
AND 
((MH "Mortality+") OR  "(MH "Survival+") OR Mortality OR  Death OR  Deaths 
OR Survival) 
AND 
((MH  "Emergency Service+") OR (MH "Intensive Care Units+") 
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OR "Emergency service" OR  "Emergency services" OR  "Emergency department" 
OR "Emergency departments" OR  "Emergency Units" OR  "Emergency Unit" OR 
"Intensive Care Units" OR “Intensive Care Unit" OR ICU OR ICUs) 
AND 
(Timing OR Time OR  Hour OR  Hours) 
AND 
(Administration OR Appropriate OR Appropriateness OR Compliance) 
AND 
(randomized OR randomised OR placebo OR randomly OR trial OR groups OR (MH 
"Epidemiology+") OR “case control” OR Cohort OR "Follow up" OR Observational 
OR longitudinal OR Prospective OR retrospective OR "cross sectional" OR 
Investigated OR Analysis) 
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Table Liu-Doi Quality Scale  
Item Questions Score 
1=Yes/Not 
applicable, 
0=No/Unclear 
 Design bias  
1 What was the type of design? 
a) randomized and allocation concealed – 3 points 
b) randomized only – 2 points 
c) prospective cohort – 1 point 
d) retrospective cohort or case control – 0 point 
[note of  b)：1. Was the study described as randomized (this includes 
words such as randomly, random, and randomization)?  Yes=1, No=0 
2.Was the method used to generate the sequence of randomization 
described and appropriate (table of random numbers, computer-
generated, etc)? Yes=1, No=0] 
 
2 Was the duration of active treatment appropriate for the demonstration 
of study outcome (e.g. >= 6 months for neurological recovery of 
SCI)*? 
 
 Selection bias  
3 Did the inclusion/exclusion criteria remain consistent across the 
comparison groups of the study? 
[Abstractor: to use this question for studies with one group, the focus 
of the question on comparison groups and related response categories 
would need to be changed to individuals]  
 
4 Was the strategy for recruitment into the study the same across 
comparison groups (e.g. not from same populations or both groups 
were not recruited over the same time period)? 
[Abstractor: in case-control studies were the controls randomly 
selected from the source population for cases over the same time 
period? To use this question for studies with one group, the focus of 
the question on comparison groups and related response categories 
would need to be changed to individuals] 
 
5 Was the interval between the start of intervention and outcome the 
same across comparison groups, or if different, were appropriate 
analyses used to equalize this (e.g. time-to-event analyses)? 
[Abstractor: in case-control studies, was the interval between the start 
of intervention and outcome the same for cases and controls? To use 
this question for studies with one group, the focus of the question on 
comparison groups and related response categories would need to be 
changed to individuals] 
 
6 Was attrition < 20%, or if not, was follow-up done for these subjects 
to ensure their loss was not related to outcome? 
[Abstractor: in case-control and cross-sectional studies the non-
response rate is used instead of attrition.] 
 
 Information bias  
7 Were the outcomes of interest in the study pre-specified?  
8 Were reproducible measures (clear name of predefined scale or clear 
details of non-predefined scale were presented) of study outcomes 
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*Please make a decision based on the target health condition in your study 
**Please make a decision on the important confounder (s) in your study (maximum 5 
founders recommended); 1 point if the answer is YES to each question/confounder, 
otherwise 0 point. 
implemented in the same way across comparison groups?  
[Abstractor: for case-control studies the focus is on case definition. To 
use this question for studies with one group, the focus of the question 
on comparison groups and related response categories would need to 
be changed to individuals.] 
9 Were the outcome assessors blinded to the nature of intervention or 
control (e.g. Qigong, acupuncture or usual medical care)? 
 
10 Were the subjects blinded to the nature of intervention or control (e.g. 
Qigong, acupuncture or usual medical care)? 
 
11 Apart from blinding, were any other safeguards described and used for 
assuring the reliability of study outcomes (e.g. any of validated 
instruments, duplicated measurement, independent assessment)? 
 
12 Were data assessed and recorded in the same way for both comparison 
groups and across time points? 
[Abstractor: to use this question for studies with one group, the focus 
of the question on comparison groups and related response categories 
would need to be changed to individuals at two time points] 
 
13 Were interventions/exposures clearly defined (all essential 
components were described) and implemented in the same way across 
both study groups? 
[Abstractor: to use this question for studies with one group, the focus 
of the question on comparison groups and related response categories 
would need to be changed to individuals] 
 
 Confounding bias  
14 Were the groups similar at baseline in key confounding variables or if 
not were steps taken to achieve comparability of key confounders (e.g. 
through matching, stratification, interaction terms, multivariate 
analysis, or other statistical adjustment such as instrumental 
variables)? 
a) age 
b) duration of disease 
c) level of lesion 
d) severity of SCI  
e) gender 
[Abstractor: to use this question for studies with one group, the focus 
of the question on comparison groups and related response categories 
would need to be changed to temporal trends in these variables and 
related co-interventions over time for the individuals] 
 
 Analytical bias  
15 Were effect sizes based on the data available at post assessment or 
pre-defined subgroups rather than a post hoc portion of the data? 
 
16 Was intention-to-treat analyses conducted for the outcome of interest?  
17 Were all data available (i.e. they did not need to be estimated from 
results)?  
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1. Was the study described as randomized (this includes words such as 
randomly, random, and randomization)? 
Yes=1, No=0 
2. Was the method used to generate the sequence of randomization 
described and appropriate (table of random numbers, computer-
generated, etc)? 
Yes=1, No=0 
3. Was the study described as double blind? 
Yes=1, No=0 
4. Was the method of double blinding described and appropriate (identical 
placebo, active placebo, dummy, etc)? 
Yes=1, No=0 
5. Was there a description of withdrawals and dropouts? 
Yes=1, No=0 
6. Deduct one point if the method used to generate the sequence of 
randomization was described and it was inappropriate (e.g. patients were 
allocated alternately, or according to date of birth, hospital number, etc). 
Described but inappropriate = -1, Described and appropriate = 0 
7. Deduct one point if the study was described as double blind but the 
method of blinding was inappropriate (e.g. comparison of tablet vs. 
injection with no double dummy). 
Described but inappropriate = -1, Described and appropriate = 0 
 
 
 
 
